These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1036 related articles for article (PubMed ID: 17649784)
1. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784 [TBL] [Abstract][Full Text] [Related]
2. PINP as serum marker of metastatic spread to the bone in breast cancer patients. Lüftner D; Jozereau D; Schildhauer S; Geppert R; Müller C; Fiolka G; Wernecke KD; Possinger K Anticancer Res; 2005; 25(3A):1491-9. PubMed ID: 16033050 [TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Tähtelä R; Thölix E Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558 [TBL] [Abstract][Full Text] [Related]
4. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845 [TBL] [Abstract][Full Text] [Related]
5. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. Koizumi M; Yonese J; Fukui I; Ogata E J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449 [TBL] [Abstract][Full Text] [Related]
6. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Oremek G; Sauer-Eppel H; Klepzig M Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805 [TBL] [Abstract][Full Text] [Related]
7. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881 [TBL] [Abstract][Full Text] [Related]
8. Type I collagen metabolites as tumor markers in patients with lung carcinoma. Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235 [TBL] [Abstract][Full Text] [Related]
9. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320 [TBL] [Abstract][Full Text] [Related]
10. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Koizumi M; Takahashi S; Ogata E Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607 [TBL] [Abstract][Full Text] [Related]
11. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361 [TBL] [Abstract][Full Text] [Related]
12. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929 [TBL] [Abstract][Full Text] [Related]
13. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy. Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763 [TBL] [Abstract][Full Text] [Related]
14. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Lüftner D; Richter A; Geppert R; Wernecke KD; Possinger K Anticancer Res; 2003; 23(2A):1017-26. PubMed ID: 12820341 [TBL] [Abstract][Full Text] [Related]
15. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Klepzig M; Sauer-Eppel H; Jonas D; Oremek GM Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432 [TBL] [Abstract][Full Text] [Related]
16. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961 [TBL] [Abstract][Full Text] [Related]
17. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Klepzig M; Jonas D; Oremek GM Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219 [TBL] [Abstract][Full Text] [Related]
18. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779 [TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP]. Kobayashi Y; Ochi M; Tokue A Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802 [TBL] [Abstract][Full Text] [Related]
20. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]